Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Progress Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St slightly higher as SK Hynix's stellar debut limits losses in chip stocks
- Oil prices fall on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
FBR Capital Remains Bullish on Seres Therapeutics (MCRB); Says Sell-Off is 'Overdone'
August 12, 2016 8:01 AM EDTFBR Capital maintained an Outperform rating on Seres Therapeutics (NASDAQ: MCRB), and cut the price target to $23.00 (from $43.00), following the company's recent sell-off.
Analyst Vernon Bernardino commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic... More
Seres Therapeutics (MCRB) Misses Q2 EPS by 24c
August 11, 2016 7:02 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.70), $0.24 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.2 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
... More